Haleon
As of the edition of 20 October 2026, Haleon runs 11 drugs, 11 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ibuprofen | none listed | 11 |
| Nicotine | none listed | 1 |
| Esomeprazole | none listed | 2 |
| Diclofenac | none listed | 7 |
| Fluticasone propionate | none listed | 2 |
| Fluticasone furoate | Ends 2027 (patent) | 0 |
| Fluticasone | none listed | 2 |
| Orlistat | none listed | 2 |
| Clemastine | none listed | 0 |
| Nizatidine | none listed | 2 |
| Docosanol | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| ATP4A Potassium-transporting ATPase alpha chain 1 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Haleon needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.